Application of leucyl-tRNA synthetase 2

A technology of synthase and leucyl, which is applied to medical preparations, enzymes, ligases and other directions containing active ingredients, can solve the problems of premature ovarian failure, lack of research on protein function and mechanism, and inhibition of yeast mitochondrial function, etc. The effect of promoting post-repair

Active Publication Date: 2021-12-10
THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Subsequent studies have found that LARS2 gene mutations are associated with hearing loss and premature ovarian failure in Perrault syndrome, lethal multisystem insufficiency in infants and young children, and mitochond

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of leucyl-tRNA synthetase 2
  • Application of leucyl-tRNA synthetase 2
  • Application of leucyl-tRNA synthetase 2

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Embodiment 1 is combined with attached Figure 1-8 ; Application of leucyl-tRNA synthetase 2 to muscle repair after injury.

[0023] Application of leucyl-tRNA synthetase 2 to repair of skeletal muscle after injury.

[0024] Application of leucyl-tRNA synthetase 2 in regulating repair of damaged skeletal muscle by affecting mitochondrial function.

[0025] Application of leucyl-tRNA synthetase 2 in the repair of ischemic injured skeletal muscle.

[0026] Use of leucyl-tRNA synthetase 2 in myoblast differentiation.

[0027] Use of leucyl-tRNA synthetase 2 in the maintenance of mitochondrial stability.

[0028] Leucyl-tRNA synthetase 2 is LARS2.

Embodiment 2

[0029] Embodiment 2, in conjunction with attached Figure 1-4 , the application of leucyl-tRNA synthetase 2 in the repair of ischemic injured skeletal muscle,

[0030] To clarify the role of LARS2 in the repair of ischemic injured skeletal muscle;

[0031] 1. The study used canagliflozin, which can down-regulate LARS2 protein, or a blank control orally orally administered C57BL / 6 mice for 7 days, and then ligated the right femoral artery to create a lower limb ischemia model. Then the mice continued to gavage canagliflozin or blank control for 3 / 7 / 14 days;

[0032] 2. The mice were anesthetized 14 days after the ischemic injury and the tibialis anterior muscle was isolated to detect the functional repair of the ischemic injured skeletal muscle;

[0033] 3. The tibialis anterior muscle and gastrocnemius muscle of the mouse were collected on 3 / 7 / 14 days after the ischemic injury, and frozen sections were made. Sections were used to observe skeletal muscle repair.

Embodiment 3

[0034] Embodiment 3, in conjunction with attached Figure 1-4 , the application of leucyl-tRNA synthetase 2 in the repair of ischemic injured skeletal muscle,

[0035] 1. Six-week-old male C57BL / 6 mice were fed with a high-fat diet (60kcal%; Beijing Botai Hongda Biotechnology Co., Ltd.) for 6-8 weeks to make them obese and abnormal glucose tolerance. Then streptozotocin was used for continuous intraperitoneal injection at 40 mg / kg for 4 days (the mice were fasted for 12 hours before each injection). After the above-mentioned injections, the mice should pay attention to changing cages and keeping them clean to avoid infection. After continuing to feed for 1 week, the weight of the mice gradually recovered and a stable increase in blood sugar appeared. A blood sugar over 250 mg / dl was considered a successful model.

[0036] 2. The above-mentioned mice were divided into a control group and a canagliflozin (CANA) group (specifically inhibiting the expression of LARS2 in skeleta...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of leucyl-tRNA synthetase 2 to repair after skeletal muscle injury. The skeletal muscle repairing agent has the advantage of effectively promoting skeletal muscle repairing after injury.

Description

technical field [0001] The present invention relates to the application of leucyl-tRNA synthetase 2. Background technique [0002] Skeletal muscle is formed by the orderly arrangement of multinucleated myotubes formed by the fusion of mononuclear myoblasts. This process of fusion of mononuclear myoblasts to form multinucleated muscle fibers is called myogenesis, which is a key step in skeletal muscle development and injury repair. Myogenesis is a highly ordered and coordinated process. It relies on the activation, proliferation, and directed differentiation of skeletal muscle stem cells (MuSC) into myoblasts, and then fuses to form multinucleated myotubes. Under the stimulus of injury, quiescent MuSCs are activated and differentiate into clusters of vigorously proliferating myoblasts for a short period of time. These cell clusters migrate to the injury site, further differentiate and fuse with each other to form multinucleated myofibers to replace the damaged skeletal mus...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/43A61P21/00
CPCA61K38/43C12Y601/01004A61P21/00
Inventor 林以诺吕心煌从晓霞郦铮铮南金良卢星梅陈骁王智廷周日永
Owner THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap